Barrionuevo Elizabeth, Cayrol Florencia, Cremaschi Graciela A, Cornier Patricia G, Boggián Dora B, Delpiccolo Carina M L, Mata Ernesto G, Roguin Leonor P, Blank Viviana C
Laboratorio de Oncología y Transducción de Señales, Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Departamento de Química Biológica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, CONICET, Buenos Aires, Argentina.
Laboratorio de Neuroinmunomodulación y Oncología Molecular, Instituto de Investigaciones Biomédicas, Facultad de Ciencias Médicas, Pontificia Universidad Católica Argentina (UCA), CONICET, Buenos Aires, Argentina.
Front Pharmacol. 2020 Feb 25;11:127. doi: 10.3389/fphar.2020.00127. eCollection 2020.
The synthetic triazolylpeptidyl penicillin derivative, named TAP7f, has been previously characterized as an effective antitumor agent and against B16-F0 melanoma cells. In this study, we investigated the anti-metastatic potential of this compound on highly metastatic murine B16-F10 and human A375 melanoma cells. We found that TAP7f inhibited cell adhesion, migration and invasion in a dose-dependent manner. Additionally, we demonstrated that TAP7f downregulated integrin αvβ3 expression and Wnt/β-catenin pathway, a signaling cascade commonly related to tumor invasion and metastasis. Thus, TAP7f reduced both the enzymatic activity and the expression levels of matrix-metalloproteinases-2 and -9 in a time dependent manner. Moreover, TAP7f inhibited the expression of the transcription factor Snail and the mesenchymal markers vimentin, and N-cadherin, and up-regulated the expression of the epithelial marker E-cadherin, suggesting that the penicillin derivative affects epithelial-mesenchymal transition. Results obtained were supported by those obtained in a B16-F10-bearing mice metastatic model, that showed a significant TAP7f inhibition of lung metastasis. These findings suggest the potential of TAP7f as a chemotherapeutic agent for the treatment of metastatic melanoma.
合成的三唑基肽基青霉素衍生物,名为TAP7f,先前已被表征为一种有效的抗肿瘤剂,可对抗B16-F0黑色素瘤细胞。在本研究中,我们研究了该化合物对高转移性小鼠B16-F10和人A375黑色素瘤细胞的抗转移潜力。我们发现TAP7f以剂量依赖性方式抑制细胞粘附、迁移和侵袭。此外,我们证明TAP7f下调整合素αvβ3表达和Wnt/β-连环蛋白通路,这是一种通常与肿瘤侵袭和转移相关的信号级联反应。因此,TAP7f以时间依赖性方式降低基质金属蛋白酶-2和-9的酶活性和表达水平。此外,TAP7f抑制转录因子Snail以及间充质标志物波形蛋白和N-钙粘蛋白的表达,并上调上皮标志物E-钙粘蛋白的表达,表明该青霉素衍生物影响上皮-间质转化。在携带B16-F10的小鼠转移模型中获得的结果支持了这些发现,该模型显示TAP7f对肺转移有显著抑制作用。这些发现表明TAP7f作为治疗转移性黑色素瘤的化疗药物的潜力。